Aegis Therapeutics, LLC And Albany Medical College Combine Discoveries To Create A Novel Anti-Obesity Nasal Spray
10/19/2005 5:10:05 PM
SAN DIEGO--(BUSINESS WIRE)--May 16, 2005--Aegis Therapeutics officials and Albany Medical College researchers announced today that they have entered into a license agreement relating to the Albany Medical College's patented anti-obesity peptide. Aegis plans to employ its patented Intravail(TM) intranasal peptide delivery technology with the Albany Medical College's anti-obesity peptide to assess its commercial potential and to seek appropriate partnerships with pharmaceutical companies interested in the obesity market.
"Following the discovery of the hormone leptin and its critical role in curbing appetite by Jeffrey Friedman and his colleagues in 1995, many believed that the ability to treat obesity was imminent," said Edward T. Maggio, Ph.D., President and CEO of Aegis. "As a result several clinical trials ensued to combat obesity with recombinant leptin, but these were unsuccessful. This joint agreement between Aegis Therapeutics and Albany Medical College brings renewed hope that a pharmaceutical treatment for obesity is possible."
comments powered by